Published in Cancer Res on April 15, 1992
Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer (2009) 5.31
Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol (1995) 2.41
A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell (1996) 2.39
Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol Cell Biol (1998) 2.29
Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J (1997) 2.21
The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression. Glycoconj J (2007) 1.74
Tissue architecture: the ultimate regulator of epithelial function? Philos Trans R Soc Lond B Biol Sci (1998) 1.40
Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol Ther (2009) 1.39
MT1-MMP mediates MUC1 shedding independent of TACE/ADAM17. Biochem J (2004) 1.32
Regulation of the metastatic cell phenotype by sialylated glycans. Cancer Metastasis Rev (2012) 1.32
Alterations in the composition of the supramucosal defense barrier in relation to disease severity of ulcerative colitis. J Histochem Cytochem (2006) 1.17
Macrophage-tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin. Immunology (1999) 1.16
Glc1.8 from Microplitis demolitor bracovirus induces a loss of adhesion and phagocytosis in insect high five and S2 cells. J Virol (2005) 1.13
Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene. Proc Natl Acad Sci U S A (1993) 1.13
Molecular cloning of Porimin, a novel cell surface receptor mediating oncotic cell death. Proc Natl Acad Sci U S A (2001) 1.12
Molecular characterization of gp40, a mucin-type glycoprotein from the apical plasma membrane of Madin-Darby canine kidney cells (type I). Biochem J (1997) 1.10
An abundantly expressed mucin-like protein from Toxocara canis infective larvae: the precursor of the larval surface coat glycoproteins. Proc Natl Acad Sci U S A (1996) 1.05
Prognostic significance of mucin expression in gastric carcinoma. Dig Dis Sci (2004) 1.03
Mucin expression in pleomorphic adenoma of salivary gland: a potential role for MUC1 as a marker to predict recurrence. J Clin Pathol (2004) 1.01
The mucin epiglycanin on TA3/Ha carcinoma cells prevents alpha 6 beta 4-mediated adhesion to laminin and kalinin and E-cadherin-mediated cell-cell interaction. J Cell Biol (1994) 1.01
Mucin gene expression in human male urogenital tract epithelia. Hum Reprod (2006) 1.01
Antiadhesive character of mucin O-glycans at the apical surface of corneal epithelial cells. Invest Ophthalmol Vis Sci (2008) 1.00
Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells. Immunology (2000) 0.94
Sialomucin complex in the rat respiratory tract: a model for its role in epithelial protection. Biochem J (1998) 0.94
Expression of MUC1 recognized by monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of advanced colon carcinoma. Clin Exp Metastasis (2004) 0.93
Natural and Induced Humoral Responses to MUC1. Cancers (Basel) (2011) 0.93
Interactions between MUC1 and p120 catenin regulate dynamic features of cell adhesion, motility, and metastasis. Cancer Res (2013) 0.92
MUC1 in carcinoma-host interactions. Glycoconj J (2001) 0.92
Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues. World J Gastroenterol (2006) 0.91
MUC1 inhibits cell proliferation by a beta-catenin-dependent mechanism. Biochim Biophys Acta (2007) 0.90
Expression of MUC1 mucins inversely correlated with post-surgical survival of renal cell carcinoma patients. Br J Cancer (1999) 0.89
Mucin 21/epiglycanin modulates cell adhesion. J Biol Chem (2010) 0.88
Circulating tumour markers in breast cancer. Eur J Nucl Med Mol Imaging (2004) 0.86
MUC1 is involved in trophoblast transendothelial migration. Biochim Biophys Acta (2007) 0.85
MUC1-C nuclear localization drives invasiveness of renal cancer cells through a sheddase/gamma secretase dependent pathway. Oncotarget (2014) 0.85
Peroxisome proliferator-activated receptor gamma activation inhibits progesterone-stimulated human MUC1 expression. Mol Endocrinol (2010) 0.84
Enhancement of metastatic ability by ectopic expression of ST6GalNAcI on a gastric cancer cell line in a mouse model. Clin Exp Metastasis (2012) 0.83
MUC1c regulates cell survival in pancreatic cancer by preventing lysosomal permeabilization. PLoS One (2012) 0.82
Mucinous differentiation features associated with hormonal escape in a human prostate cancer xenograft. Br J Cancer (2004) 0.81
MUC1 expressed in PanC1 cells decreases adhesion to type 1 collagen but increases contraction in collagen lattices. Am J Pathol (1996) 0.80
Immune Responses to the MUC1 Mucin. Pathol Oncol Res (1995) 0.78
Expression of mucin genes in the human testis and its relationship to spermatogenesis. Yonsei Med J (2005) 0.77
Expression of MUC1 recognized by a monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of carcinoma of the gallbladder. Clin Exp Metastasis (2004) 0.77
Sialylation of E-cadherin does not change the spontaneous or ET-18-OMe-mediated aggregation of MCF-7 human breast cancer cells. Clin Exp Metastasis (1999) 0.76
MUC1 Is Expressed by Human Skin Fibroblasts and Plays a Role in Cell Adhesion and Migration. Biores Open Access (2014) 0.76
Purification and characterization of the MUC1 mucin-type glycoprotein, epitectin, from human urine: structures of the major oligosaccharide alditols. Glycoconj J (1998) 0.76
Mucin1 expression in focal epidermal dysplasia of actinic keratosis. Ann Transl Med (2015) 0.75
Embryo implantation evolved from an ancestral inflammatory attachment reaction. Proc Natl Acad Sci U S A (2017) 0.75
Absence of correlation of MUC1 expression to malignant behavior of renal cell carcinoma in experimental systems. Clin Exp Metastasis (2000) 0.75
Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol (1995) 2.41
A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell (1996) 2.39
Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer (1984) 2.12
Cell membrane-associated mucins and their adhesion-modulating property. Trends Biochem Sci (1992) 2.11
Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost (1999) 2.04
Cell-associated episialin is a complex containing two proteins derived from a common precursor. J Biol Chem (1992) 1.90
Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A) Stroke (1998) 1.63
Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. J Biol Chem (1990) 1.63
Development of mouse mammary gland: identification of stages in differentiation of luminal and myoepithelial cells using monoclonal antibodies and polyvalent antiserum against keratin. J Histochem Cytochem (1986) 1.61
Acquisition of proviral DNA of mouse mammary tumor virus in thymic leukemia cells from GR mice. J Virol (1982) 1.53
A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood (1997) 1.42
MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol (1998) 1.41
Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol (1993) 1.40
Haplotypes of the EPCR gene, plasma sEPCR levels and the risk of deep venous thrombosis. J Thromb Haemost (2004) 1.33
Characterization of the mouse met proto-oncogene. Oncogene (1988) 1.31
Biosynthesis of MAM-6, an epithelial sialomucin. Evidence for involvement of a rare proteolytic cleavage step in the endoplasmic reticulum. J Biol Chem (1988) 1.23
A single nucleotide polymorphism in an exon dictates allele dependent differential splicing of episialin mRNA. Nucleic Acids Res (1991) 1.22
MUC1/episialin: a critical barrier in the female reproductive tract. J Reprod Immunol (1999) 1.22
A mouse homeobox containing gene on chromosome 11: sequence and tissue-specific expression. Nucleic Acids Res (1987) 1.21
The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma. Histopathology (2007) 1.21
A stat-responsive element in the promoter of the episialin/MUC1 gene is involved in its overexpression in carcinoma cells. J Biol Chem (2000) 1.19
Localization of a gene for expression of mouse mammary tumor virus antigens in the GR/Mtv-2- mouse strain. J Exp Med (1980) 1.17
Metaxin, a gene contiguous to both thrombospondin 3 and glucocerebrosidase, is required for embryonic development in the mouse: implications for Gaucher disease. Proc Natl Acad Sci U S A (1995) 1.15
The epithelial sialomucin, episialin, is sialylated during recycling. J Biol Chem (1993) 1.14
Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost (2005) 1.14
MAM-6 antigen, a new serum marker for breast cancer monitoring. Cancer Res (1986) 1.11
ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden. J Thromb Haemost (2005) 1.08
Identification of a cellular receptor for mouse mammary tumor virus and mapping of its gene to chromosome 16. J Virol (1983) 1.05
A nonsense mutation in the cathepsin K gene observed in a family with pycnodysostosis. Genome Res (1996) 1.04
Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis. Thromb Haemost (2001) 1.01
Complexity of MAM-6, an epithelial sialomucin associated with carcinomas. Cancer Res (1989) 1.00
G20210A is a functional mutation in the prothrombin gene; effect on protein levels and 3'-end formation. J Thromb Haemost (2004) 1.00
Genetic mapping of Pim-1 putative oncogene to mouse chromosome 17. Somat Cell Mol Genet (1986) 0.99
Characterization and molecular cloning of a novel MUC1 protein, devoid of tandem repeats, expressed in human breast cancer tissue. Eur J Biochem (1994) 0.98
Is episialin/MUC1 involved in breast cancer progression? Cancer Lett (1995) 0.98
Immunohistochemical localization of the epithelial marker MAM-6 in invasive malignancies and highly dysplastic adenomas of the large intestine. Lab Invest (1987) 0.98
The mouse episialin (Muc1) gene and its promoter: rapid evolution of the repetitive domain in the protein. Biochem Biophys Res Commun (1991) 0.96
Immunohistochemical study of mucin carbohydrates and core proteins in hepatolithiasis and cholangiocarcinoma. Int J Cancer (1993) 0.94
Beta 2 adrenergic receptor polymorphisms: association with factor VIII and von Willebrand factor levels and the risk of venous thrombosis. J Thromb Haemost (2005) 0.94
Characterization of a single LSO crystal layer high resolution research tomograph. Phys Med Biol (2003) 0.93
Endocytosis and intracellular routing of an antibody-ricin A chain conjugate. Cancer Res (1988) 0.93
Polymorphisms in the prothrombin gene and their association with plasma prothrombin levels. Thromb Haemost (2001) 0.92
Assignment of estradiol receptor gene to mouse chromosome 10. J Steroid Biochem (1988) 0.92
Functional characterization of transcription factor binding sites for HNF1-alpha, HNF3-beta (FOXA2), HNF4-alpha, Sp1 and Sp3 in the human prothrombin gene enhancer. J Thromb Haemost (2003) 0.92
Polymorphism 10034C>T is located in a region regulating polyadenylation of FGG transcripts and influences the fibrinogen gamma'/gammaA mRNA ratio. J Thromb Haemost (2007) 0.92
Epitopes with diagnostic and prognostic significance co-expressed on a human breast carcinoma-associated antigen. Eur J Cancer Clin Oncol (1986) 0.91
Distribution of virus particles and mammary tumor virus antigens in mouse mammary tumors, transformed BALB-c mouse kidney cells, and GR ascites leukemia cells. J Natl Cancer Inst (1974) 0.91
Characterization of the genetic defects in recessive type 1 and type 3 von Willebrand disease patients of Italian origin. Thromb Haemost (1998) 0.89
The 46C-->T polymorphism in the factor XII gene (F12) and the risk of venous thrombosis. J Thromb Haemost (2005) 0.89
Functional analysis of two prothrombin 3'-untranslated region variants: the C20209T variant, mainly found among African-Americans, and the C20209A variant. J Thromb Haemost (2006) 0.89
Characterization of the human extracellular matrix protein 1 gene on chromosome 1q21. Matrix Biol (1997) 0.88
Lipopolysaccharide induction of tissue factor in THP-1 cells involves Jun protein phosphorylation and nuclear factor kappaB nuclear translocation. J Biol Chem (1999) 0.88
Monoclonal antibodies against human acid alpha-glucosidase. Biochim Biophys Acta (1981) 0.88
An online database of mutations and polymorphisms in and around the coagulation factor V gene. J Thromb Haemost (2007) 0.88
NCAM and lung cancer. Int J Cancer Suppl (1994) 0.87
A mutation in the thrombomodulin gene, 127G to A coding for Ala25Thr, and the risk of myocardial infarction in men. Thromb Haemost (1998) 0.87
Comparison of circulating MAM-6 and CEA levels and correlation with the estrogen receptor in patients with breast cancer. Int J Cancer (1987) 0.87
Prognostic value of surface antigens in primary human breast carcinomas, detected by monoclonal antibodies. Cancer Res (1985) 0.87
Age dependence and genetics of expression of ecotropic murine leukemia virus in SJL/J mice. J Natl Cancer Inst (1979) 0.86
Novel antigenic specificity involving the blood group antigen, Lea, in combination with onco-developmental antigen, SSEA-1, recognized by two monoclonal antibodies to human milk-fat globule membranes. Biochem Biophys Res Commun (1985) 0.86
High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene. Br J Haematol (2001) 0.85
Homozygous C2362F von Willebrand factor induces intracellular retention of mutant von Willebrand factor resulting in autosomal recessive severe von Willebrand disease. Br J Haematol (2006) 0.85
Monoclonal antibodies to epithelial sialomucins recognize epitopes at different cellular sites in adenolymphomas of the parotid gland. Int J Cancer Suppl (1988) 0.85
Preferential expression of cellular retinoic acid binding protein in a subpopulation of neural cells in the developing mouse embryo. Differentiation (1989) 0.84
Linkage analysis of factor VIII and von Willebrand factor loci as quantitative trait loci. J Thromb Haemost (2003) 0.84
Sequence variants and haplotypes of the factor IX gene and the risk of venous thrombosis. J Thromb Haemost (2008) 0.84
Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues. J Thromb Haemost (2004) 0.83
Alkyl-lysophospholipid 1-O-octadecyl-2-O-methyl- glycerophosphocholine induces invasion through episialin-mediated neutralization of E-cadherin in human mammary MCF-7 cells in vitro. Int J Cancer (2001) 0.83
A novel quantitative multiplex NASBA method: application to measuring tissue factor and CD14 mRNA levels in human monocytes. Nucleic Acids Res (1999) 0.83
Use of a monoclonal antibody to distinguish between precursor and mature forms of human lysosomal alpha-glucosidase. Eur J Biochem (1984) 0.83
Identification of a mouse gene required for binding of Rauscher MuLV envelope gp70. Somatic Cell Genet (1979) 0.82
Mouse interferon alpha and beta genes are linked at the centromere proximal region of chromosome 4. J Gen Virol (1985) 0.82
The association of prothrombin A19911G polymorphism with plasma prothrombin activity and venous thrombosis: results of the MEGA study, a large population-based case-control study. J Thromb Haemost (2006) 0.82
Genetic differences in BALB/c sublines. Curr Top Microbiol Immunol (1985) 0.82
Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA (2001) 0.81
Selectin haplotypes and the risk of venous thrombosis: influence of linkage disequilibrium with the factor V Leiden mutation. J Thromb Haemost (2007) 0.81
The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis. Thromb Haemost (2000) 0.80
Immunoscintigraphy of small-cell lung cancer xenografts with anti neural cell adhesion molecule monoclonal antibody, 123C3: improvement of tumour uptake by internalisation. Br J Cancer (1996) 0.80
Isolation of two distinct epithelial cell lines from a single feline mammary carcinoma with different tumorigenic potential in nude mice and expressing different levels of epidermal growth factor receptors. Cancer Res (1991) 0.80
Depolarized expression of episialin (EMA, MUC1) in lung adenocarcinoma is associated with tumor progression. Anticancer Res (1998) 0.79
The HR2 haplotype of factor V is not associated with the risk of myocardial infarction. Thromb Haemost (2000) 0.79
Radioimmunotherapy of small-cell lung cancer xenografts using 131I-labelled anti-NCAM monoclonal antibody 123C3. Cancer Immunol Immunother (1995) 0.79
Simultaneous chemical induction of MTV and MLV in vitro. Eur J Cancer (1977) 0.79
Physical mapping of two temperature-sensitive adenovirus mutants affected in the DNA polymerase and DNA binding protein. Virus Genes (1990) 0.79
Sex hormone-binding globulin levels are not causally related to venous thrombosis risk in women not using hormonal contraceptives. J Thromb Haemost (2012) 0.79
Functional variation in the arginine vasopressin 2 receptor as a modifier of human plasma von Willebrand factor levels. J Thromb Haemost (2010) 0.79